Loss of Pax3, a developmentally regulated transcription factor expressed in pre-migratory neural crest, results in severe developmental defects and embryonic lethality. Although Pax3 mutations produce profound phenotypes, the intrinsic transcriptional activation exhibited by Pax3 is surprisingly modest. We postulated the existence of transcriptional co-activators that function with Pax3 to mediate developmental functions. A high-throughput screen identified the Hippo effector proteins Taz and Yap65 as Pax3 co-activators. Synergistic co-activation of target genes by Pax3-Taz/Yap65 requires DNA binding by Pax3, is Tead-independent, and is regulated by Hippo kinases Mst1 and Lats2. In vivo, Pax3 and Yap65 co-localize in the nucleus of neural crest progenitors in the dorsal neural tube. Neural crest deletion of Taz and Yap65 results in embryonic lethal neural crest defects and decreased expression of the Pax3 target gene, Mitf. These results suggest that Pax3 activity is regulated by the Hippo pathway and that Pax factors are Hippo effectors.
INTRODUCTION
Neural crest is a multipotent population of cells arising from the embryonic dorsal neural tube. Following neural tube closure, neural crest cells undergo an epithelial-mesenchymal transition (EMT), migrate along defined routes and contribute to multiple organs and tissues including craniofacial cartilage, bone and the pigmented cells of the skin (melanocytes). Neural crest induction is dependent upon inductive signals from neighboring tissues. Wnt and Bmp signaling has been implicated in this process, though the precise details of how inductive signals result in EMT, migration and cell specification remain to be elucidated.
Pax3 plays a critical role in pre-migratory neural crest and is thought to orchestrate neural crest-specific gene expression (Goulding et al., 1991) . Mutation of Pax3 in the mouse results in embryonic lethality and a wide array of neural crest abnormalities, including pigmentation defects and congenital heart disease. In the melanocyte lineage, Pax3 functions with Sox10 to directly activate the expression of microphthalmia-associated transcription factor (Mitf), which is required for melanogenesis. In humans, PAX3 mutations result in Waardenburg syndrome, characterized by pigmentation defects and deafness due to neural crest deficiencies.
Other members of the Pax family, consisting of nine related factors in mammals, are expressed in various organs and tissues where they play critical roles in organogenesis. Pax transcription factors are characterized by the presence of a DNA-binding domain termed the paired domain that mediates sequence-specific protein-DNA interactions (Chi and Epstein, 2002) . Although Pax genes also encode a C-terminal transactivation domain, in vitro assays reveal relatively weak intrinsic activation capacity. The trans-activation potential of Pax factors may be modulated by interacting proteins. For example, a Pax3/Pax7 binding protein, Pax3/7BP, can recruit H3K4 histone methyltransferase activity to Pax target genes in C2C12 myoblasts, thus regulating cell proliferation and the expression of the Pax target genes Id3 and Cdc20 (Diao et al., 2012) . Pax6 can interact with homeodomain-interacting protein kinase 2 (Hipk2). Hipk2 phosphorylates Pax6 and enhances Pax6 interaction with p300, thereby increasing transcriptional activation (Kim et al., 2006) . However, the functional role of Pax interacting factors has not been examined in detail in vivo.
The Hippo signaling pathway is a kinase cascade, initially identified in Drosophila, that governs overall organ size through regulation of proliferation and apoptosis (Justice et al., 1995; Xu et al., 1995; Tapon et al., 2002; Harvey et al., 2003; Wu et al., 2003) . Following the identification in Drosophila, mammalian Hippo signaling molecules have been defined. The upstream kinases Mst1 and Mst2 interact with a scaffolding protein Salvadore1. Mst1 and Mst2 phosphorylate the downstream kinases Lats1 and Lats2 along with associated scaffolding proteins Mobkl1A/Mobkl1b. Lats1 and Lats2 phosphorylate downstream effector molecules of the Hippo pathway, Taz and Yap65. When Hippo signaling is inactive, Taz and Yap65 are de-phosphorylated, located in the nucleus and act as transcriptional coactivators. Canonical transcriptional activation is achieved through association with Tead factors that serve as the DNA-binding partners for Taz and Yap65. Following activation of the Hippo pathway, Taz and Yap65 are phosphorylated and sequestered in the cytoplasm, thus abrogating transcriptional co-activation. In addition to Tead factors, Taz and Yap65 are capable of interacting in vitro with other proteins including Runx2, ErbB4, p63/p73, Tbx5 and Smads-1/2/3/7. (Zaidi et al., 2004; Komuro et al., 2003; Strano et al., 2001; Alarcon et al., 2009; Murakami et al., 2005 , Varelas et al., 2008 Ferrigno et al., 2002) . We and others have previously shown that Taz/Yap65, via interaction with Tead, can contribute to regulation of Pax3 gene expression in premigratory neural crest (Milewski et al., 2004; Degenhardt et al., 2010; Gee et al., 2011) , and Taz was also identified as a Pax3-interacting protein in a yeast two-hybrid assay (Murakami et al., 2006) . Interestingly, Hippo signaling has been shown to promote cellular proliferation and EMT (Lei et al., 2008) , two processes critical for the in vivo function of neural crest.
In this manuscript, we demonstrate a potent, synergistic activation of target genes by Pax3 and Taz/Yap65. Target gene activation requires an intact Pax3 DNA-binding domain and is Tead-independent. Hippo kinases, Mst1 and Lats2, can inhibit the transcriptional activity of the complex, demonstrating a role for Hippo signaling. Pax3 and Yap65 are co-expressed in the dorsal neural tube at the time of neural crest delamination. Loss of Taz/Yap65 in these pre-migratory neural crest cells results in down-regulation of Mitf, a target of coordinated Pax-Hippo signaling. Other members of the Pax family are also co-activated by Taz/Yap65, suggesting that one output of Hippo signaling is activation of Pax targets.
RESULTS

A high-throughput screen identifies Taz and Yap65 as Pax3 co-activators
To identify potential Pax3 co-activator molecules, we conducted a high-throughput screen by co-transfecting a Pax3 expression plasmid along with a Pax3 luciferase reporter vector with each of approximately 15,000 human and mouse cDNAs arrayed in 384-well plates in HEK293T cells (Mammalian Gene Collection MGCv1 library, Open BioSystems). The Pax3 reporter contains five Pax3 paired domain DNA binding sequences (Epstein et al., 1994) upstream of a synthetic minimal promoter directing firefly luciferase expression. Potential Pax3 co-activators were identified as cDNAs that generated luciferase activity greater than that of Pax3 alone. Both Taz and Yap65 were identified among the top 5 coactivators (Table S1 ). We confirmed that Pax3 can interact with Yap65, like Taz (Murakami et al., 2006) , using the Duolink® system which utilizes a proximity ligation assay to monitor protein-protein interactions in situ ( Figure S1A ). Independent validation experiments in HEK293T cells confirmed the ability of either Taz or Yap65 to induce synergistic transactivation of the synthetic Pax3 luciferase reporter when transfected with Pax3 ( Figure  1A ). When Pax3, Taz or Yap65 was expressed independently, each induced only ~4-5 fold activation. In contrast, when Pax3 was co-expressed with either Taz or Yap65, over 60-fold activation was induced ( Figure 1A ). The nine mammalian Pax genes can be divided into 4 families based upon sequence conservation, and members of each Pax sub-family can function synergistically with Taz and Yap65 ( Figure S1 ).
Several Pax family members, including Pax3, contain a homeodomain DNA binding domain in addition to the paired domain, and Pax3 can occupy both paired and homeodomain recognition motifs in vivo (Soleimani et al., 2012) . To determine if the presence of Taz or Yap65 enhances Pax3 activation at homeodomain sequences, we generated a Paxhomeodomain luciferase reporter containing nine Pax homeodomain DNA binding motifs upstream of a synthetic minimal promoter directing firefly luciferase expression. Pax3 could synergize with either Taz or Yap65 to activate the synthetic homeodomain reporter ( Figure  1B ).
Pax3-Taz/Yap65 activation requires Pax3 DNA binding and is Tead-independent
Taz and Yap65 are generally thought to act by interacting with Tead factors, which are expressed ubiquitously, although alternative DNA binding proteins have been described to interact with Taz or Yap65 in vitro (Zhang et al., 2009; Zhao et al., 2008; Zaidi et al., 2004; Komuro et al., 2003; Strano et al., 2001; Murakami et al., 2006) . To establish if DNA binding by Pax3 is required for transcriptional co-activation observed in our assays, we examined the effect of a missense mutation in the Pax3 paired-domain found in a patient with Waardenburg syndrome that impairs sequence-specific DNA interactions (Epstein et al., 1995) . The Pax3 DNA binding mutant (Pax3-PD-Mutant) was unable to synergize with either Taz or Yap65 ( Figure 1C ). These data suggest that Pax3 must associate with DNA to mediate the robust activation observed in the presence of Taz and/or Yap65. The Pax3-PDMutant was able to synergize with Taz or Yap65 when a homeodomain reporter was used and protein expression was confirmed by immunoblot ( Figure S2 ). Furthermore, inhibition of Tead activity by expression of a dominant-negative Tead mutant (DN-Tead1) consisting of a truncated protein that retains DNA-binding capacity but cannot recruit Taz (Zhang et al., 2009; Zhao et al., 2008) failed to prevent Pax3 synergy with Taz ( Figure 1D ), although it efficiently abolished Taz activation of a Tead-dependent reporter ( Figure 1E ). Pax7, which is closely related to Pax3 and is co-expressed in the dorsal neural tube, can also synergize with Taz in a Tead-independent manner ( Figure 1F ). Thus, we infer that Taz and Yap65 can act as direct co-activators of Pax3/7 target genes.
Pax3 and Yap65 co-localize in the dorsal neural tube
Pax3 is actively transcribed in the dorsal neural tube during early/mid gestation (~E8-10) when neural crest cells undergo an epithelial-to-mesenchymal transition, delaminate, and migrate throughout the body (Goulding et al., 1991) . Yap65 is ubiquitously expressed at similar stages (Morin-Kensicki et al., 2006) . At E9.5 we observed Pax3 and Yap65 nuclear co-localization in the dorsal neural tube (Figure 2 ), the dorsal root ganglia which is derived from neural crest ( 
Loss of Taz and Yap in neural crest results in craniofacial defects and down-regulation of Mitf
To examine the biological significance of Taz and Yap65 in neural crest, floxed alleles were utilized to delete Taz and Yap65 in premigratory neural crest using Wnt1-Cre (Xin et al., 2011; Xin et al., 2013 Figure 3 ). Within the neural tubes of the E10.5 Yap65/Taz deletion embryos, there was no detectable change in the percentage of proliferating or apoptotic cells ( Figure S3 ). Grossly, hemorrhages were evident in the branchial arch regions in the Yap65/Taz double null embryos ( Figure 3Q,R) . Histologic analysis revealed deficiencies of facial mesenchyme in the maxillary and mandibular branchial arches ( Figure  3S ,T), regions normally populated by neural crest. Deletion of both Yap65 alleles and a single Taz allele resulted in a similar hemorrhagic phenotype ( Figure 3M ,N) although facial mesenchyme appeared intact ( Figure 3O ,P), and mice of this genotype were not identified postnatally (Table 1) . In embryos in which both Taz alleles and a single Yap65 allele were removed, the embryos were phenotypically normal at E10.5 ( Figure 3I -L) and they survived postnatally (Table 1) .
We followed the fate of neural crest cells with or without Yap65 and Taz by including a R26tdTomato (R26 Tom/+ ) Cre reporter allele. Wnt1-derived cells can be identified in resultant embryos by expression of tdTomato and detection with an anti-RFP antibody. Examination of control and double mutant embryos at E10.5 showed that neural crest migration was grossly intact (Figure 4 ). Neural crest derivatives populated the branchial arches and peripheral ganglia ( Figure 4B ,E) and Pax3 expression was maintained in double null embryos ( Figure 4C,F) . Serial sections of fate-mapped E10.5 embryos revealed intact migration of neural crest throughout the embryo where they populated regions of presumptive facial mesenchyme, the peripheral nervous system and the enteric ganglia ( Figure 4G ,H,L,M). Neurofilament expression by neural crest populating peripheral ganglia appeared normal, as determined by co-staining of fate-mapped neural crest cells with the 2H3 anti-neurofilament antibody ( Figure 4I ,J,N,O). Enteric ganglia derivatives expressed Sox10 at levels indistinguishable from controls ( Figure 4K ,P). Thus, many aspects of neural crest migration and fate-specification appeared intact despite the loss of Taz/Yap65.
Mitf is coordinately regulated by Pax3 and Yap/Taz
Neural crest derived cells were also observed adjacent to surface ectoderm in both control and double null embryos where migrating melanoblasts are normally found ( Figure 5A,B) . In control embryos, these cells expressed Mitf, a transcriptional activator of melanogenesis regulated by Pax3 (Watanabe et al., 1998) (Figure 5A ). However, in double knockout embryos, Mitf expression was markedly down-regulated in these neural crest derivatives ( Figure 5B ). Quantitation of RFP/Mitf positive cells adjacent to and within the surface ectoderm revealed a significant decrease in the percentage of RFP+ cells that also expressed Mitf in Yap65/Taz null embryos ( Figure 5C ). In mouse embryonic fibroblasts derived from Taz flox/flox ;Yap flox/flox embryos, treatment with a Cre virus to delete both alleles of Yap65 and Taz produced a significant decrease in Mitf expression ( Figure 5D ). Dopachrome tautomerase (Dct) is a direct transcriptional target of Mitf (Lang et al., 2005) and was similarly decreased following deletion of Yap65 and Taz ( Figure 5D ). We sought to determine if altered Mitf expression in Yap/Taz double knockout embryos was due to loss of synergy between Pax3 and Yap/Taz, or if this was a result of Tead-dependent Yap/Taz gene regulation. Regulatory elements controlling Mitf expression have been extensively characterized previously (Watanabe et al., 1998; Bondurand et al., 2000; Potterf et al., 2000) . Both Pax3 and Pax7 can synergize with Taz and Yap65 to activate a Mitf-luciferase reporter construct ( Figure 5F , G). Although 18 potential Tead binding sites are located in the Mitf promoter/enhancer region included in this assay ( Figure 5E ), DN-Tead1 failed to significantly impair synergistic Pax-Taz/Yap65 co-activation ( Figure 5H,I ), suggesting that Mitf activation by Pax3 and Taz is Tead-independent.
Two Pax3 paired-domain binding sites have been described within this Mitf enhancer: site P1 at position −260 to −244 and site P2 at position −40 to −26 upstream of the transcription start site (Watanabe et al., 1998; Bondurand et al., 2000; Potterf et al., 2000) . Sequence analysis utilizing the TRANSFAC database identified an additional previously uncharacterized potential Pax3 binding site, which we termed P3, located at position −160 to −143 relative to the transcription start site. A 519 base pair (bp) fragment of the Mitf enhancer, which contains the P1, P2 and P3 sites, retained the ability to be synergistically activated by Pax3 with Taz or Yap65 with activity comparable to the full length Mitf reporter ( Figure S4 ). Each Pax3 binding site was then evaluated individually in ~100-200 bp Mitf promoter/enhancer fragments. Fragments containing P2 and P3 exhibited coactivation with Taz and Yap65, but the coactivation at site P1 was not significant in the context of the enhancer fragment. Mutation of the Pax3 binding sites within P2 and P3 led to a statistically significant decrease in the observed coactivation with Taz and Yap65. The P2 and P3 fragments each contain a single predicted Tead binding site, but DN-Tead1 did not significantly decrease Pax3-Taz or Pax3-Yap65 coactivation of the P2, P3 or 519 bp Mitf reporter ( Figure S5 ). Taken together, we interpret these results to indicate that P2 and P3, but not P1, act as docking sites for a Pax3-Taz/Yap65 co-activation complex.
Hippo kinases Mst1 and Lats2 can inhibit Pax3-Taz/Yap65 synergistic activation
Taz and Yap65 are downstream effectors of the Hippo signaling pathway that is composed of a series of regulatory protein kinases, including Mst and Lats. Activation of the Hippo pathway culminates in phosphorylation of Taz/Yap65, which induces translocation to the cytoplasm and abrogation of nuclear functions. Serine residue 89 of the Taz protein was previously demonstrated to be a critical residue for Lats kinase phosphorylation (Lei et al., 2008) . Upon mutation to alanine, TazS89A gains resistance to Lats regulation and is constitutively nuclear (Lei et al., 2008) . When Pax3 was co-expressed with TazS89A there was over 130-fold activation of a Pax3 reporter ( Figure 6A ), consistent with constitutive activation. TazS89A was even more potent than wild type Taz, suggesting basal activity of Hippo signaling under these experimental conditions.
We probed the ability of upstream Hippo kinases Mst1 and Lats2 to modulate Pax3-Taz/ Yap65 transcriptional synergy. Both Mst1 and Lats2 inhibited Pax3-Taz and Pax3-Yap65 co-activation ( Figure 6B-E) . Kinase inactive mutants of Mst1 or Lats2, Mst1KI (Mst1-K59R) or LATS2KI (LATS2-D809A) respectively, were relatively ineffective at inhibiting Pax3-Taz and Pax3-Yap65 co-activation ( Figure 6B-E) . Immunoblot analysis confirmed that the wildtype and kinase inactive forms of each Hippo kinase were expressed at equivalent protein levels ( Figure 6F-G) . LATS2 also significantly inhibited co-activation of the endogenous Mitf enhancer by Pax3-Taz/Yap65 (Figure 6H-I) . In contrast, expression of LATS2KI did not alter Pax3-Taz or Pax3-Yap65 co-activation at the Mitf enhancer ( Figure  6H-I) . Thus, transcriptional synergy between Pax factors and Yap/Taz can be modulated by upstream regulators of the Hippo pathway.
We further examined the ability to Pax3 and Pax7 to co-activate another previously described Pax target gene. Myf5 is a regulator of myogenic determination that is another example of a direct transcriptional target of Pax3/7 (Bajard et al., 2006) . Pax3 and Pax7 each functioned with Taz or Yap65 to co-activate a previously described Myf5 enhancer ( Figure  S6A-C) . This activation was Tead-independent, as the presence of DN-Tead1 did not alter the co-activation ( Figure S6D,E) . Further Lats2, but not Lats2KI, significantly inhibited Pax3-Taz/Yap65-mediated activation of the Myf5 reporter ( Figure S6F ,G).
DISCUSSION
Hippo signaling is a critical regulator of proliferation and EMT during development and in cancer (Lei et al., 2008) . In this study we demonstrate that the downstream effector molecules of Hippo signaling, Taz and Yap65, can function as co-activators of Pax3. This complex requires Pax3 to act as the DNA binding moiety and is regulated by upstream Hippo kinases. Unlike canonical Hippo signaling, the Pax3-Taz/Yap65 complex does not require Tead factors to mediate activity. Deletion of Taz and Yap65 in pre-migratory neural crest resulted in craniofacial defects, similar to those seen in the absence of Pax3 and Pax7 (Mansouri and Gruss, 1998) , and down-regulation of the Pax3 target, Mitf. In vitro data suggests that another Pax3 target, Myf5, can also be coordinately regulated by Pax3 and Yap/Taz. The Pax3-Taz/Yap65 complex produces potent transcriptional activation. In vivo, this complex is likely to include additional factors that may vary with context. Candidates include the previously identified Pax3/7 binding protein, Pax3/7BP which recruits an H3K4 histone methyltransferase to target gene promoters (Diao et al., 2012) . Taz has been shown to interact with the histone acetyl transferases PCAF and p300 (Murakami et al., 2005) . This interaction greatly enhances Taz transcriptional activity at an atrial natriuretic factor promoter reporter construct (Murakami et al., 2005) . Future studies will elucidate the nature of additional Pax/Taz/Yap complex subunits.
Since Pax factors from all Pax families can utilize Taz and Yap65 as coactivators, Hippo signaling could be a common means to regulate activity of many Pax target genes in diverse developmental contexts. Pax genes function in multiple developing tissues and play key roles in organogenesis. Pax6, for example, is critical for formation of the eye and is mutated in inherited causes of blindness. Pax2 functions in early kidney formation, Pax8 in the thymus and has also been shown to co-activate with Taz, and Pax1/9 in the skeleton (Di Palma et al., 2009) . Hippo signaling is known to regulate organ size. The functional interaction of Pax proteins with Yap65 and Taz may provide a physical and functional mechanism to link organogenesis with the regulation of organ size. Likewise, disruption of Pax function has been implicated in cancer, and the role of Pax/Hippo synergy in oncogenesis will be an important area of future investigation.
EXPERIMENTAL PROCEDURES Plasmids
The firefly-luciferase reporter construct 5xPax3BS was provided by M. Buckingham (Relaix et al., 2003) and subcloned into pGL4.27 (Promega). To generate a Pax3-homeodomain reporter construct, a previously identified Pax homeodomain-binding motif (Soleimani et al., 2012) , TAATTGATTA, was synthetically generated and re-iterated nine times. This sequence was then cloned upstream of pGL4.27 for use in luciferase assays (Promega). An MITF reporter previously published, containing approximately 2 kb of the 5' proximal human promoter (chr3:69,934,337-69,936,682 (hg38) , Lang et al., 2005) was subcloned into pGL4.27 (Promega). 8xGTIIC, a Tead reporter, was provided by S. Piccolo ( (Dupont et al., 2011) , Addgene plasmid 34615). Murine Taz and Taz-S89A expression vectors were described previously ( (Kanai et al., 2000) , Addgene plasmids 19025 and 19026) and were subcloned into pCMV-Sport6 (Invitrogen). Murine Yap65 was expressed in pCMV-Sport6 (Invitrogen) as described previously (Milewski et al., 2004) . Dominant negative human TEAD1 (DN-TEAD1) was provided by Kun-Liang Guan (Zhang et al., 2009; Zhao et al., 2008) . Murine hippo kinases Mst1 and Mst1-KI were previously described ( (Lin et al., 2002) , Addgene plasmids 1965 and 1966) . Expression plasmids for human hippo kinases LATS2 and LATS2-KI were provided by D. Pan (Dong et al., 2007) . The murine Pax3 expression construct was previously described (Lang et al., 2000) and was subcloned into pCMV-Sport6 (Invitrogen). The murine Pax3 paired domain mutant (Pax3-PD-Mutant) contains a single cytosine to thymine mutation that produces a proline to leucine change at amino acid 50 which prevents Pax3 binding to DNA sequences, was previously described (Epstein et al., 1995) and was subcloned into pCMV-Sport6 (Invitrogen). Human PAX7 was expressed in pcDNA3 (Invitrogen).
Cell Culture and Luciferase Assay
HEK293T cells were maintained at 37°C with 5% CO 2 in DMEM supplemented with 10% fetal bovine serum, penicillin and streptomycin. All HEK293T cell transfections were completed using FuGene6 (Roche). Experiments utilized 250 ng of the specified fireflyluciferase reporter constructs, 80 ng Taz/Yap65, 40 ng Pax expression vector and 75 ng pGL2-Basic-renilla luciferase (Promega). In experiments with Mst1, Mst1-KI, LATS2 or LATS2-KI, 120 ng of the kinase expression vector was included. All transfections maintained an equal concentration of total DNA with the inclusion of the pCMV-Sport6 empty vector (Invitrogen). Cellular extracts were collected 48 hours post-transfection for use in a dual-luciferase assay (Promega). Twenty microliters (μl) of cellular extract was used to assess firefly and renilla luciferase activities and luciferase activity was normalized to the renilla activity. All experiments were performed in duplicate on at least three separate occasions. Statistical differences between conditions were analyzed using ANOVA, with a Tukey-Kramer post-hoc comparison test.
Western Blot
HEK293T cells were transfected with 2 ug of the specified Hippo kinase: Mst1, Mst1KI, LATS2, LATS2-KI. Mst1 and Mst1KI contain an N-terminal FLAG epitope tag while LATS2 and LATS2KI contain an N-terminal myc epitope tag. A non-transfected plate of cells was processed in parallel as a control. 48 hours post-transfection, cells were lysed in RIPA buffer (150 mm NaCl, 50 mm Tris-Base, pH 7.5, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS) plus protease inhibitors (Complete Mini, Roche). All lysates were quantitated with a BCA Assay (Promega) and an equal amount of total protein was loaded per well of a 4-12% gradient gel and run at 120V for 2 hours. Blots were transferred overnight at 4°C, at 20V onto PVDF membrane (Invitrogen). Membranes were blocked in 10% non-fat dry milk/ TBS-T and incubated in primary antibody overnight: M2-FLAG (mouse monoclonal, Sigma), myc (mouse monoclonal, Cell Signaling #2276), or actin (rabbit polyclonal, Cell Signaling, #4970). All blots were probed with horseradish peroxidase (HRP) conjugated secondary antibody for 1 hour with either anti-mouse secondary (Cell Signaling) or antirabbit secondary (Cell Signaling). Blots were developed using ECL Prime (Amersham).
Histology and Immunofluorescence
Samples were harvested, fixed overnight in 4% paraformaldehyde and dehydrated through an ethanol series. All samples were paraffin-embedded and sectioned. Antibodies used for immunofluorescence were anti-Pax3 mouse monoclonal (developed by C.P. Hematoxylin and eosin (H&E) staining was completed using a standard protocol.
Melanocyte Quantitation
Transverse sections from Wnt1-Cre;Taz flox/+ ;Yap flox/+ ;R26 Tom/+ and Wnt1-Cre;Taz flox/flox ;Yap flox/flox ;R26 Tom/+ E10.5 embryos were co-stained for RFP and Mitf. Cells greater than 100μm from the surface ectoderm were excluded from analysis. Seven sections from three independent embryos were included in the analysis which totaled 60 RFP+ cells in control embryos and 62 RFP+ cells in null embryos. Data is reported as an average percentage of each field totaled + SEM. Statistical differences between conditions were analyzed using a Student's t-test.
Mouse Embryo Fibroblast Preparation
Mouse Embryo Fibroblasts (MEFs) were isolated from E14.5 Taz flox/flox ;Yap flox/flox embryos as described (Connor 2000) . Briefly, E14.5 embryos were collected, the heads and internal organs were removed and the remains were washed twice in PBS. Embryos were then dissociated by passage through a 16-gauge needle and incubated in a trypsin solution for 5 minutes at 37°C. The resulting cells were then triturated and incubated for another 5 minutes at 37°C, an equal volume of MEF media was added and incubated for 5 minutes at RT. After centrifugation, the cell pellet was resuspended in MEF media, plated and incubated at 37°C. Cells were grown to confluence, then trypsinized and replated for treatment. In order to delete the floxed Taz and Yap65 alleles, MEFs were treated for 48 hours with an adenoassociated virus expressing a constitutively active Cre-recombinase (AAV1-CMV-Cre, Penn Vector Core, University of Pennsylvania). 
RNA isolation
Mice
All mice were maintained on a mixed genetic background. Wnt1-Cre (Jiang et al., 2000) , Yap flox/+ (Xin et al., 2011) and Taz flox/+ (Xin et al., 2013) alleles were genotyped as previously described. The Yap flox/+ and Taz flox/+ alleles were developed in the laboratory of Dr. Eric N. Olson at the University of Texas Southwestern Medical Center, Dallas, Texas. R26tdTomato mice (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J) were obtained from Jackson Labs (strain number 007914). All animal protocols were approved by the University of Pennsylvania Institutional Animal Care and Use Committee. In all experiments, luciferase activity was first normalized to the activity of a cotransfected renilla luciferase construct, then to the activity observed in the absence of specificed cDNAs (lane 1). All experiments were performed in duplicate a minimum of three individual occasions. Data depicted are the mean + standard error of the mean (SEM). Statistics were completed using an ANOVA with a Tukey-Kramer post-hoc comparison test. *** p<0.001, * p<0.05. 
